Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Equity Average (2017 - 2025)

UroGen Pharma's Equity Average history spans 9 years, with the latest figure at -$110.4 million for Q4 2025.

  • For Q4 2025, Equity Average fell 1421.7% year-over-year to -$110.4 million; the TTM value through Dec 2025 reached -$110.4 million, down 1421.7%, while the annual FY2025 figure was -$57.1 million, 54.4% down from the prior year.
  • Equity Average reached -$110.4 million in Q4 2025 per URGN's latest filing, down from -$104.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $86.4 million in Q1 2021 to a low of -$127.5 million in Q2 2023.
  • Average Equity Average over 5 years is -$32.7 million, with a median of -$40.5 million recorded in 2022.
  • Peak YoY movement for Equity Average: crashed 2277.5% in 2023, then soared 130.94% in 2024.
  • A 5-year view of Equity Average shows it stood at $20.0 million in 2021, then tumbled by 482.1% to -$76.3 million in 2022, then rose by 29.77% to -$53.6 million in 2023, then skyrocketed by 115.59% to $8.4 million in 2024, then crashed by 1421.7% to -$110.4 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Equity Average are -$110.4 million (Q4 2025), -$104.4 million (Q3 2025), and -$69.9 million (Q2 2025).